Victoza beats Byetta

Head-to-head comparison suggests Novo Nordisk's GLP-1 agonist Victoza (liraglutide) is more effective than Amylin/Lilly's Byetta (exenatide) at lowering blood sugar levels. The randomized open-label LEAD-6 study of 464 type 2 diabetes patients who failed to achieve desired targets on standard meds showed Victoza produced a significantly greater drop in HbA1C compared to twice-daily Byetta (1.12 percent versus 0.79 percent). Another study, also presented at the American Diabetes Association meeting June 8, shows those results are long-lasting. But efficacy won't be enough to make liraglutide competitive, and safety issues aren't likely to go away soon. An FDA panel split its vote on approval in light of reports that Victoza raises the risk of thyroid tumors in rodents (1Pharmaceutical Approvals Monthly April 2009, In Brief). Victoza's marketing application remains pending at FDA despite the March 23 user fee date

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

EU Pharma Reform: Council Proposal A ‘Step In The Right Direction’ But ‘More Work To Be Done’

 

Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.